Metronidazole Dawa

Metronidazole, the active ingredient in Metronidazole Dawa, is a nitroimidazole antibiotic presented as an oral dosage form for systemic use. It treats infections caused by susceptible anaerobic bacteria and certain protozoa in adult and pediatric patients as prescribed by a healthcare professional.

GNH USA supplies Metronidazole Dawa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards and is manufactured under GMP conditions.

Metronidazole is indicated for a range of anaerobic bacterial and protozoal infections.

- Bacterial vaginosis: eradicates Gardnerella vaginalis and restores normal vaginal flora. - Trichomoniasis: eliminates Trichomonas vaginalis and resolves genital symptoms. - Amoebiasis: treats intestinal Entamoeba histolytica infection and prevents tissue invasion. - Giardiasis: clears Giardia lamblia from the gastrointestinal tract. - Anaerobic bacterial infections: combats susceptible anaerobes in intra‑abdominal, skin and dental infections. - Clostridioides difficile infection: reduces toxin‑producing C. difficile and helps restore gut flora.

Metronidazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Metallic taste: transient metallic sensation in the mouth. - Headache: occasional dull or throbbing pain. - Diarrhea: loose stools that resolve after therapy. - Abdominal pain: cramping or discomfort in the stomach area. - Loss of appetite: reduced desire to eat.

Serious or Rare Side Effects: - Seizures: rare neurologic events requiring immediate attention. - Peripheral neuropathy: tingling or numbness in extremities. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: serious skin blistering disorder. - Liver toxicity: elevated liver enzymes or hepatitis. - Pancytopenia: reduction in blood cell counts.

Before prescribing Metronidazole, clinicians should consider several safety factors.

- Pregnancy Category B: generally considered safe in pregnancy, but use only if clearly needed. - Hepatic impairment: use with caution; monitor liver function tests. - Renal impairment: dose adjustment may be required in severe kidney disease. - Alcohol avoidance: advise patients to abstain from alcohol to prevent disulfiram‑like reactions. - Neuropathy monitoring: discontinue if signs of peripheral neuropathy develop. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Metronidazole can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Alcohol: may cause severe disulfiram‑like reaction. - Warfarin: can enhance anticoagulant effect, increasing bleeding risk. - Lithium: concurrent use may raise lithium levels and cause toxicity.

Moderate Interactions (Monitor Closely): - Cimetidine: may increase metronidazole plasma concentrations. - Oral contraceptives: efficacy may be reduced; consider alternative contraception. - Theophylline: levels may rise, requiring monitoring for toxicity.